KCNA3 and synovial sarcoma: In conclusion, the present study provides first evidence that malignant T cells from SS patients express functional Kv1.3 channels, and that Kv1.3 blockade inhibits activation induced CD25 and IL-9 expression and proliferation of SS cells, suggesting that Kv1.3 is a potential therapeutic target in SS.